Stay updated on Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    Change Detected
    Summary
    The site was updated to Revision: v3.5.0, and Lung cancer, related topics (MedlinePlus Genetics), and Revision: v3.4.3 were removed.
    Difference
    0.2%
    Check dated 2026-03-19T23:42:15.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    Lung cancer is added as a related topic and a MedlinePlus Genetics link appears under related topics. The site revision is updated to v3.4.3, replacing v3.4.2.
    Difference
    0.2%
    Check dated 2026-03-12T20:41:38.000Z thumbnail image
  4. Check
    26 days ago
    No Change Detected
  5. Check
    48 days ago
    Change Detected
    Summary
    - Minor metadata update: Revision: v3.4.2, and removal of a few related topics (Lung cancer; MedlinePlus Genetics; Revision: v3.4.1). Core study content, eligibility criteria, outcomes, and locations remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2026-02-11T23:59:35.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    Revision history updated from v3.4.0 to v3.4.1. No changes to the study content or results are evident in the visible text.
    Difference
    0.0%
    Check dated 2026-02-04T23:31:07.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    Show glossary, Lung cancer, and related topics (MedlinePlus Genetics) were added, along with updated revision information (Revision: v3.4.0). Older labels such as Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4 were removed.
    Difference
    0.3%
    Check dated 2026-01-28T22:21:52.000Z thumbnail image
  8. Check
    69 days ago
    Change Detected
    Summary
    Removed 'Lung cancer' and 'MedlinePlus Genetics' from the related topics section. This reduces metadata links without changing the study details or eligibility information.
    Difference
    0.1%
    Check dated 2026-01-21T18:10:56.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page.